Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Firstline Pembrolizumab Alone or in Combination with Pemetrexed and Carboplatin in Induction / Maintenance or Postprogression in Treating Patients with Stage IV Non-squamous Non-small Cell Lung Cancer

Multiple Cancer Types

This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or without pembrolizumab works better in treating patients with non-squamous non-small cell cancer.
Lung, Non Small Cell
III
Horn, Leora
NCT03793179
ECOGTHOEA5163

An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Multiple Cancer Types

Hematologic, Leukemia, Myelodysplastic Syndrome
II
Savona, Michael
NCT04093570
VICCHEM1969

Early Palliative Care in Improving Recovery and Quality of Life in Patients with Cancer Undergoing Abdominal Surgery, the SCOPE Trial

Multiple Cancer Types

This trial studies early palliative care in improving recovery and quality of life in patients with cancer undergoing abdominal surgery. Frequently people diagnosed with cancer experience physical and emotional symptoms during the course of their disease. Introduction to a team of clinicians that specialize in the lessening of many of these distressing symptoms may improve overall care. This team of clinicians is called the palliative care team and they focus on ways to improve pain and other symptom management (i.e. shortness of breath, fatigue, anxiety, etc.) and to assist patients and their families in coping with the emotional, social, and spiritual issues associated with a cancer diagnosis. This study is being done to see if receiving palliative care earlier is more useful compared to receiving palliative care late in the course of illness.
Bladder, Colon, Gastrointestinal, Gynecologic, Liver, Ovarian, Pancreatic, Supportive Care, Urologic
N/A
Shinall, Ricky
NCT03436290
VICCSUPP1971

Characterization of Central Pain Syndrome in Survivors of Head and Neck Cancer

Head/Neck

This trial studies the characterization of central pain syndrome in survivors of head and neck cancer. Many head and neck cancer patients have pain after they have completed treatment. Cancer and its treatment may change how the brain manages pain. This can make treatment of post-treatment pain more challenging for health care provides. This trial is being done to better understand how the brain is responding to pain.
Head/Neck
N/A
Lou, Dianne
NCT04128267
VICCHN1982

Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC

Breast

This is a phase Ib / II Study of Leronlimab (PRO 140) combined with Carboplatin in Patients with CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC). Study population will consist of patients with CCR5-positive, locally advanced or metastatic triple-negative breast cancer (mTNBC) who are naïve to chemotherapy in metastatic setting but have been exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings (first-line).
Breast
I/II
Abramson, Vandana
NCT03838367
VICCBREP1983

Covered Metal Stents versus Uncovered Metal Stents for the Treatment of Jaundice due to Pancreatic Cancer, Cholangiocarcinoma, or Other Metastatic Malignancies

Multiple Cancer Types

This trial studies how well covered metal stents versus uncovered metal stents work in treating patients with jaundice due to pancreatic cancer, cholangiocarcinoma (bile duct), or other malignancies that have spread to other places in the body (metastatic). Jaundice can make the skin and urine appear very yellow and cause itching throughout the body. Pancreatic cancer, cholangiocarcinoma, or other metastatic malignancies can cause jaundice by blocking the bile duct. The bile duct is a tube-like structure that drains the liver. To maintain an opening in the bile duct, a stent is placed. Uncovered self-expanding metal biliary stents have a bare metal scaffold that the tissue tends to grow into and thus blocks the stent from draining, while covered self-expanding metal biliary stents have a polyurethane coating that may prevent the tissue from growing into the stent and thus blocking the stent. It is not yet known whether covered or uncovered metal stents may work better in treating patients with jaundice.
Gastrointestinal, Pancreatic
N/A
Yachimski, Patrick
NCT01905384
VICCGI1984

Avelumab with Binimetinib, Utomilumab, or anti-OX40 Antibody PF-04518600 in Treating Patients with Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Breast

This phase II trial studies how well avelumab in combination with binimetinib, utomilumab, or anti-OX40 antibody PF-04518600 works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patients immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope that this induction will improve the response to immunotherapy with avelumab. Patients on this trial will receive two weeks of treatment with one of three treatments to stimulate the bodies immune system, including the monoclonal antibodies utomilumab and the anti-OX40 antibody PF-04518600 which may help the body's immune system attack the cancer, and could interfere with the ability of tumor cells to grow and spread. The third medication is called binimetinib , which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may help activate the immune system. It is not yet known whether giving avelumab in combination with binimetinib, utomilumab, or anti-OX40 antibody PF-04518600 will work better in treating patients with triple negative breast cancer.
Breast
II
Mayer, Ingrid
NCT03971409
VICCBRE1987

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Miscellaneous

This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-PBMC-HPV as monotherapy and in combination with atezolizumab in HLA-A*02+ patients with recurrent, locally advanced or metastatic human papillomavirus strain 16 positive (HPV16+) solid tumors.
Miscellaneous
I
Eng, Cathy
NCT04084951
VICCGIP1990

Rapid On Site Evaluation of Pleural Touch Preparations in Diagnosing Malignant Pleural Effusion in Patients Undergoing Pleuroscopy

Lung

This trial studies how well rapid on site evaluation of pleural touch preparations works in diagnosing cancerous fluid in between the linings of the lungs (malignant pleural effusion) in patients undergoing a pleuroscopy. A type of laboratory testing called rapid on site evaluation of pleural touch preparations that uses pleural biopsy tissue samples collected during an already-scheduled pleuroscopy may be able to diagnose malignant pleural effusion.
Lung
N/A
Maldonado, Fabien
NCT03868579
VICCTHO1991

Cancer Patient Safety Learning Laboratory (CaPSLL): Preventing Clinical Deterioration in Outpatients

Multiple Cancer Types

Head/Neck, Lung
N/A
Weinger, Matthew
VICCMD1998

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: